Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA [10-20] trial of empagliflozin in adults with type 2 diabetes and severe chronic kidney disease
2025-522119-41-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Change in mean urinary albumin creatinine ratio and Change in mean urinary protein creatinine ratio. Planned start May 2026; status: authorised.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-522119-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522119-41-00.